Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)

OREANDA-NEWS. July 16, 2015. The INPULSIS^® clinical trials showed that OFEV^® had a consistent effect on annual rate of FVC decline, with a 50% reduction in the decline of lung function.² OFEV^® is the only treatment to significantly reduce the risk of adjudicated acute IPF exacerbations^? by 68%.² Acute exacerbations in IPF are associated with high morbidity and mortality. They are the leading cause of hospitalisation and death in patients with IPF.^5,6,7,8

In both INPULSIS^® trials, the most common adverse events were gastrointestinal in nature, of mild or moderate intensity, generally manageable and rarely leading to treatment discontinuation.²

About IPF
IPF is a fatal lung disease, with a median survival of 2 – 3 years after diagnosis.³ It causes progressive scarring of the lungs, resulting in continual and irreversible deterioration in lung function and difficulty breathing.³ Worldwide, IPF affects as many as 14 – 43 people per 100,000,⁹ most commonly over the age of 50.³

^***This conditional recommendation means that clinicians are encouraged to discuss preferences with their patients when making treatment decisions.